To Determine Tolerability to Glucagon Infusion in Obese Subjects (GIO)

Clinical Trial ID NCT02817659

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.	Lancet	2009	7.24
2	Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.	Endocrinology	2011	1.32
3	New approaches to measuring nausea.	CMAJ	1985	1.30
4	Hormonal control of substrate cycling in humans.	J Clin Invest	1988	1.22
5	Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.	Diabetes	2012	1.13
6	Effect of glucagon on food intake and body weight in man.	J Appl Physiol	1957	1.10
7	The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans.	Int J Obes Relat Metab Disord	2000	0.94
8	Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency.	J Clin Endocrinol Metab	1987	0.92
9	Insulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man.	Metabolism	1994	0.89
10	Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.	Diabetes Obes Metab	2015	0.81